1. ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY. (11th November 2019) Authors: De la Fuente, Macarena I; Colman, Howard; Rosenthal, Mark; Van Tine, Brian A; Fonkem, Ekokobe; Walbert, Tobias; Milhem, Mohammed; Lipford, Kate; Forsyth, Sanjeev; Guichard, Sylvie; Brevard, Julie; Mikhailov, Yelena; Thomson, Blythe; Monga, Varun Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Issue 1 (25th May 2022) Authors: de la Fuente, Macarena I; Colman, Howard; Rosenthal, Mark; Van Tine, Brian A; Levacic, Danijela; Walbert, Tobias; Gan, Hui K; Vieito, Maria; Milhem, Mohammed M; Lipford, Kathryn; Forsyth, Sanjeev; Guichard, Sylvie M; Mikhailov, Yelena; Sedkov, Alexander; Brevard, Julie; Kelly, Patrick F; Mohamed,... Journal: Neuro-oncology Issue: Volume 25:Issue 1(2023) Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Issue 1 (January 2023) Authors: Watts, Justin M; Baer, Maria R; Yang, Jay; Prebet, Thomas; Lee, Sangmin; Schiller, Gary J; Dinner, Shira N; Pigneux, Arnaud; Montesinos, Pau; Wang, Eunice S; Seiter, Karen P; Wei, Andrew H; De Botton, Stephane; Arnan, Montserrat; Donnellan, Will; Schwarer, Anthony P; Récher, Christian; Jonas, Bri... Journal: Lancet Issue: Volume 10:Issue 1(2023) Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Issue 5 (12th January 2022) Authors: Forsyth, Sanjeev; Schroeder, Patricia; Geib, James; Vrishabhendra, Leela; Konstantinidis, Diamantis G.; LaSalvia, Kari; Ribadeneira, Maria D.; Wu, Eric; Kelly, Patrick; Kalfa, Theodosia A. Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 5(2022) Page Start: 654 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SCIDOT-42. FT-2102 – A POTENT AND SELECTIVE BRAIN PENETRANT INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE. (11th November 2019) Authors: Ribadeneira, Maria; Guichard, Sylvie; Yao, Lili; Toms, Angela; Forsyth, Sanjeev; Thomson, Blythe; Ehrlich, Paul Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗